Adial ADIL 深 沪
交易中 05-11 10:54:48 美东时间
1.45
+0.010
+0.69%
华盛通- 最 高1.65
- 今 开1.47
- 成交量 5.12万股
- 最 低 1.38
- 昨 收 1.44
- 总市值 3.45万
- 52周最高 3.673
- 市盈率 静 --
- 换手率 215.20%
- 52周最低 0.1323
- 委 比 0.00%
- 总股本 2.38万
- 历史最高 9.44
- 量 比 2.70
- 振 幅 18.75%
- 历史最低 0.08
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Nasdaq Dips 200 Points; Alphabet Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more t...
02-05 23:10
Dow Jumps Over 200 Points; Uber Shares Fall After Q4 Results
U.S. stocks traded mixed this morning, with the Dow Jones index gaining more th...
02-04 23:36
Adial Pharmaceuticals Announces Pricing of $3.6 Million Public Offering
Adial Pharmaceuticals announced a public offering of 11.1 million shares of common stock and accompanying Series D and E warrants, raising approximately $3.6 million. Series D warrants are exercisable at $0.35 per share for five years, while Series E warrants have an 18-month term. Existing Series B-1 and C-1 warrants will be amended to reduce their exercise price to $0.35 per share.
2025-06-17 12:00
【美股盤前】伊以衝突推升石油股狂飆！SK海力士股價創20年新高！美國經濟數據即將揭曉，美股能否再創新高？
伊以衝突持續，石油股繼續受益大漲；SK海力士擬建造韓國最大AI數據中心，股價創下近20年新高；美國即將公佈多項經濟數據，美股將繼續上漲？
2025-06-17 11:33
Adial Pharmaceuticals Submits Briefing Package to Guide Upcoming FDA Meeting
Adial Pharmaceuticals submitted the briefing package for the rescheduled End of Phase 2 meeting on July 29 with the FDA to discuss Phase 3 clinical development of AD04 for Alcohol Use Disorder.
2025-06-16 12:00
Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
Adial Pharmaceuticals collaborates with Cytel to leverage machine learning for optimizing Phase 3 trial design of AD04, targeting AUD. The partnership identifies genetic subpopulations for higher efficacy and plans to launch the trial late 2025.
2025-06-11 12:00
